source
- GSK's B7-H3 ADC cuts osteosarcoma progression risk by 67% in Chinese phase 3 trialA phase 3 study in China evaluated GSK's B7-H3‑directed antibody‑drug conjugate, risvutatug rezetecan (ris‑rez), in patients with relapsed osteosarcoma. The trial met its primary endpoint, showing…
- US Treasury draft COINS rules could sharply limit China biotech partnershipsUS Treasury released a draft set of regulations known as the COINS rule that targets cross-border biotech transactions. The proposal would bar certain US-China deals and tighten oversight of collab…